Streetbeat News

OLK

Olink Holding AB (publ)

https://www.olink.com

CEO

Jon Heimer

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Olink Holding AB provides accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients.

Open

26.00

Mkt cap

3.2B

Volume

1.9M

High

26.08

P/E Ratio

-96.59

52-wk high

26.09

Low

25.98

Div yield

N/A

52-wk low

14.10

The UK's Competition and Markets Authority has cleared the merger between Thermo Fisher Scientific Inc. and Olink. This regulatory approval is a significant step forward for the merger process.

Portfolio Pulse from Benzinga Newsdesk

July 08, 2024 | 10:44 am

Olink has launched Target 48 Immune Surveillance, a new product aimed at setting new standards in immune biomarker profiling.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2024 | 6:47 am

Olink Holding reported its Q1 2024 earnings with a GAAP EPS of $(0.13), surpassing the $(0.16) estimate. However, its sales of $28.751M fell short of the expected $30.220M.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 10:09 am

Morgan Stanley analyst Tejas Savant has maintained an Equal-Weight rating on Olink Holding (NASDAQ:OLK) and has also maintained a price target of $26 for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 4:00 pm

Canaccord Genuity analyst Kyle Mikson reiterated a Hold rating on Olink Holding (NASDAQ:OLK) and maintained a $26 price target.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 11:59 am

Olink Holding (NASDAQ:OLK) reported Q4 earnings with an EPS of $-0.06, missing estimates by -140.0% compared to the expected $0.15. Revenue increased by $10.67 million from the same period last year. Despite past quarters showing mixed results, this quarter's earnings fell short of expectations.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 1:15 pm

Olink Holding (NASDAQ:OLK) reported Q4 earnings per share (EPS) of $(0.06), missing the analyst consensus estimate of $0.15 by 140%. Quarterly sales were $68.55M, missing the estimate of $89.86M by 23.71%. This represents a 220% decrease in EPS and an 18.43% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 12:14 pm

Thermo Fisher Scientific Inc. has extended its tender offer for all outstanding common shares and ADSs of Olink Holding AB at $26.00 per share/ADS, in cash. The offer, now expiring on January 3, 2024, has seen approximately 97.1% of Olink's outstanding shares tendered. The extension does not require action from shareholders who have already tendered their shares. Completion of the offer is subject to conditions outlined in the tender offer statement filed with the SEC.

Portfolio Pulse from Benzinga Newsdesk

December 15, 2023 | 1:09 pm

Olink Holding (NASDAQ:OLK) reported Q3 earnings with an EPS of $-0.01, beating the estimate of $-0.08 by 87.5%. Revenue increased by $12.38 million compared to the same period last year. The company had previously beaten EPS estimates last quarter, which resulted in a 1.69% share price increase the following day.

Portfolio Pulse from Benzinga Insights

November 15, 2023 | 2:45 pm

Olink Holding (NASDAQ:OLK) reported Q3 earnings per share (EPS) of $(0.01), surpassing the $(0.08) estimate, and sales of $44.15M, exceeding the $43.24M estimate. The EPS remained the same as last year, while sales saw a significant increase of 38.97% from $31.77M in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 12:14 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.